concept

CX43

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CX43: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

360Connections

4Hypotheses

0Analyses

50Outgoing

50Incoming

14Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	CX43
Key Genes/Proteins	Actin, ACTR2, ACTR3, AGING, Akt, AKT
Related Diseases	aging, Aging, Als, ALS, Alzheimer
Linked Hypotheses	1 hypotheses

Pathway Diagram

graph TD
    CX43["CX43"]
    style CX43 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    CX43 -->|"involved_in"| Blood_Brain_Barrier_Integrity["Blood-Brain Barrier Integrity"]
    CX43 -->|"interacts"| PARP1([PARP1])
    CX43 -->|"involved_in"| Blood_Brain_Barrier_Damage(Blood-Brain Barrier Damage)
    CX43 -->|"interacts"| P2_Receptors["P2 Receptors"]
    CX43 -->|"interacts"| P2_receptors["P2 receptors"]
    CX43 -.->|"inhibits"| Inflammation["Inflammation"]
    CX43 -.->|"inhibits"| Stroke["Stroke"]
    CX43 -->|"target for"| Ms["Ms"]
    CX43 -->|"target for"| Cancer["Cancer"]
    CX43 -->|"activates"| Neuroinflammation["Neuroinflammation"]
    INFLAMMATION([INFLAMMATION]) -.->|"inhibits"| CX43
    ASTROCYTES([ASTROCYTES]) -->|"expressed in"| CX43
    ASTROCYTE([ASTROCYTE]) -->|"expressed in"| CX43
    STROKE([STROKE]) -.->|"inhibits"| CX43
    AND([AND]) -->|"expressed in"| CX43
    APOPTOSIS([APOPTOSIS]) -.->|"inhibits"| CX43
    OXIDATIVE_STRESS([OXIDATIVE STRESS]) -.->|"inhibits"| CX43
    AQP4([AQP4]) -->|"expressed in"| CX43
    P38([P38]) -.->|"inhibits"| CX43
    CANCER([CANCER]) -->|"target for"| CX43

Outgoing (213)

Target	Relation	Type	Str
h-8a244611	targeted_by	hypothesis	1.00
Blood-Brain Barrier	regulates	biological_process	0.90
Blood-Brain Barrier Integrity	involved_in	process	0.88
PARP1	interacts_with	protein	0.85
Blood-Brain Barrier Damage	involved_in	phenotype	0.85
PARP1	inhibits	gene	0.80
NAD+	regulates	metabolite	0.80
P2 receptors	interacts_with	receptor	0.70
P2 Receptors	interacts_with	receptor	0.70
Alzheimer's Disease	associated_with	disease	0.70
Tumor	associated_with	disease	0.65
Amyotrophic Lateral Sclerosis	activates	disease	0.65
Leukemia	regulates	disease	0.65
Ms	therapeutic_target	disease	0.65
Aging	causes	disease	0.65
Als	associated_with	disease	0.65
Cancer	associated_with	disease	0.65
Parkinson	activates	disease	0.65
Als	inhibits	disease	0.65
Cancer	interacts_with	disease	0.65
Neurodegeneration	therapeutic_target	disease	0.65
Alzheimer	activates	disease	0.65
Pain	therapeutic_target	disease	0.65
Glioblastoma	causes	disease	0.65
Als	activates	disease	0.65
Dementia	therapeutic_target	disease	0.65
Inflammation	inhibits	disease	0.65
Tumor	activates	disease	0.65
Ms	expressed_in	disease	0.65
Pain	activates	disease	0.65
Depression	activates	disease	0.65
Alzheimer	associated_with	disease	0.65
Cardiovascular	regulates	disease	0.65
Inflammation	activates	disease	0.65
Stroke	inhibits	disease	0.65
Alzheimer	protects_against	disease	0.65
Aging	activates	disease	0.65
Autoimmune	regulates	disease	0.65
Neuroinflammation	activates	disease	0.65
Glaucoma	contributes_to	disease	0.65
Cancer	protects_against	disease	0.65
Ischemia	expressed_in	disease	0.65
Cancer	therapeutic_target	disease	0.65
ALS	inhibits	disease	0.65
Als	therapeutic_target	disease	0.65
Cardiovascular	activates	disease	0.65
Dementia	protects_against	disease	0.65
ALS	activates	disease	0.65
Alzheimer	therapeutic_target	disease	0.65
ALS	associated_with	disease	0.65

Incoming (147)

Source	Relation	Type	Str
h-8a244611	targets	hypothesis	1.00
GJA1	associated_with	gene	0.90
P38MAPK	regulates	pathway	0.80
IFN	inhibits	gene	0.70
GENES	activates	gene	0.60
RNA	activates	gene	0.60
IL-18	activates	gene	0.60
PAD4	inhibits	gene	0.60
IFN	activates	gene	0.60
CCDC88A	activates	gene	0.60
PARKINSON	activates	gene	0.60
NEURODEGENERATIVE DISEASES	activates	gene	0.60
GENE MUTATIONS	activates	gene	0.60
AMYOTROPHIC LATERAL SCLEROSIS	activates	gene	0.60
AQP4	inhibits	gene	0.60
AQUAPORIN-4	expressed_in	gene	0.60
ALZHEIMER	expressed_in	gene	0.60
ANG	expressed_in	gene	0.60
MAPK	inhibits	gene	0.60
ALZHEIMER'S DISEASE	expressed_in	gene	0.60
ALZHEIMER'S DISEASE	activates	gene	0.60
ALZHEIMER	associated_with	gene	0.60
CANCER	therapeutic_target	gene	0.60
ALZHEIMER'S DISEASE	associated_with	gene	0.60
ATP	activates	gene	0.60
ASTROCYTES	associated_with	gene	0.60
OXIDATIVE STRESS	activates	gene	0.60
TERT	activates	gene	0.60
MITOCHONDRIA	activates	gene	0.60
GJA1	associated_with	gene	0.60
GJA1	regulates	gene	0.60
AGING	activates	gene	0.60
NAD	activates	gene	0.60
PARP1	activates	gene	0.60
AND	regulates	gene	0.60
NEURON	regulates	gene	0.60
AKT	phosphorylates	gene	0.60
BRAIN INJURY	inhibits	gene	0.60
AND	inhibits	gene	0.60
ASTROCYTES	interacts_with	gene	0.60
GJA1	transports	gene	0.60
ROS	activates	gene	0.60
DRP1	activates	gene	0.60
AND	associated_with	gene	0.60
DEMENTIA	protects_against	gene	0.60
ALZHEIMER	protects_against	gene	0.60
ALZHEIMER'S DISEASE	protects_against	gene	0.60
AUTOPHAGY	regulates	gene	0.60
ACTR3	regulates	gene	0.60
NEURODEGENERATION	contributes_to	gene	0.60

Targeting Hypotheses (4)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Context-Dependent Cx43 Modulation Based on Disease Stage	0.724	cell biology	What is the relative contribution of con
CX43 hemichannel engineering enables size-selective mitochon	0.686	neurodegeneration	Mitochondrial transfer between astrocyte
TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between S	0.663	cell biology	What is the relative contribution of con
Blocking Astrocyte-Mediated Tau Re-Spreading via Cx43 Hemich	0.570	neuroscience	Trans-synaptic tau spreading and propaga

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (14)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
H₂O₂-induced oxidative stress in isolated chondrocytes	exploratory	Temporomandibular joint osteoa	0.900	0.00	Isolated chondrocytes	proposed	N/A
Unilateral anterior crossbite (UAC) model of TMJOA in rats	validation	Temporomandibular joint osteoa	0.900	0.00	Rats with unilateral anterior	proposed	N/A
Gap26 inhibitor treatment in cellular TMJOA model	exploratory	Temporomandibular joint osteoa	0.900	0.00	H₂O₂-treated chondrocytes with	proposed	N/A
Cx43 knockdown effects on mitochondrial transfer	exploratory	osteoarthritis	0.900	0.00	human bone marrow-derived MSCs	proposed	N/A
Network pharmacology analysis of QTJD active compounds and pathways	exploratory	Mycoplasma pneumoniae pneumoni	0.900	0.00	computational network analysis	proposed	N/A
Confocal imaging of MSC-chondrocyte interactions during mitochondrial	exploratory	osteoarthritis	0.850	0.00	human bone marrow-derived MSCs	proposed	N/A
Gap26 treatment in UAC rat model of TMJOA	validation	Temporomandibular joint osteoa	0.800	0.00	UAC rats treated with Gap26 in	proposed	N/A
Cx43-β-catenin protein-protein interaction analysis	exploratory	Temporomandibular joint osteoa	0.800	0.00	Cell-based protein interaction	proposed	N/A
Proposed experiment from debate on Mitochondrial transfer between astr	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$80,000
Proposed experiment from debate on Mitochondrial transfer between astr	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$100,000
AAV-LRRK2 IND-Enabling Study Design	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,500,000
Gap Junction Dysfunction Validation in Parkinson's Disease	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
AAV-LRRK2 Gene Therapy IND-Enabling Study Design	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson'	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Astrocytic Connexin43 in Alzheimer's disease: mechanisms, interaction with P2 re [PMID:41062060]	Xiong W, Su Y, Verkhratsky A, Yi C	Neuropharmacology	2026	1
Connexin43 hemichannel blockade turns microglia neuroprotective and mitigates co [PMID:40595567]	Su Y, Li H, Zhang W, Tao S, Wang Q, Zhan	Nat Commun	2025	1
Should it stay or should it go: gap junction protein GJA1/Cx43 conveys damaged l [PMID:39394955]	Domingues N, Ribeiro-Rodrigues T, Girão	Autophagy	2024	1
Connexin 43 regulates intercellular mitochondrial transfer from human mesenchyma [PMID:39390589]	Irwin RM, Thomas MA, Fahey MJ, Mayán MD,	Stem Cell Res Ther	2024	1
Astrocyte Networks as Therapeutic Targets in Glaucomatous Neurodegeneration. [PMID:34199470]	Boal AM, Risner ML, Cooper ML, Wareham L	Cells	2021	1
Connexin43 Deficiency Leads to Ventricular Arrhythmias by Reprogramming Proline [PMID:41618855]	["Ying H", "Fan H", "Wang Y", "Jiang R",	Advanced science (Weinheim, Ba	2026	0
Prenatal lipopolysaccharide exposure programs cardiac fibrosis via dysregulating [PMID:41789580]	Wen Y, Yuan Y, Zhang H, Liu Y	Molecular medicine reports	2026	0
Astrocytes Protect Brain Metastatic Breast Cancer Cells From Chemotherapy Throug [PMID:41486609]	Yakati V, Rao SS	Biotechnol Bioeng	2026	0
The AP-1 transcription factors differentially regulate Cx43 expression in a ERK1 [PMID:41930557]	Basque A, Izichkis LS, Mellet C, Martin	Reprod Biol	2026	0
Inhibition of NETs prevents doxorubicin-induced cardiotoxicity by attenuating IL [PMID:39805175]	Li K, Jiang KM, Wang Y, Hu F, Zhu XC, Su	International immunopharmacolo	2025	0
Glial cell line-derived neurotrophic factor improves impaired colonic motility i [PMID:40062335]	["Yang W", "Liu R", "Xu F"]	World journal of gastroenterol	2025	0
Astroglial toxicity promotes synaptic degeneration in the thalamocortical circui [PMID:36602862]	Marsan E, Velmeshev D, Ramsey A, Patel R	The Journal of clinical invest	2023	0
The role of vimentin, Connexin-43 proteins, and oxidative stress in the protecti [PMID:33098837]	["Abdel-Wahab B", "Salem S", "Mohammed H	European journal of pharmacolo	2021	0
Levo-corydalmine Attenuates Vincristine-Induced Neuropathic Pain in Mice by Upre [PMID:31617070]	Zhou L, Ao L, Yan Y, Li C, Li W, Ye A, L	Neurotherapeutics : the journa	2020	0
Connexin-43-dependent ATP release mediates macrophage activation during sepsis. [PMID:30735126]	["Dosch M", "Zindel J", "Jebbawi F", "Me	eLife	2019	0
Four-week individual caging of male ICR mice alters body composition without cha [PMID:29358648]	["Shin J", "Woo J", "Cho Y", "Choi Y", "	Scientific reports	2018	0
Evolution to the rescue: using comparative genomics to understand long non-codin [PMID:27573374]	["Ulitsky I"]	Nature reviews. Genetics	2016	0
Doxorubicin-Mediated Cardiotoxicity: Role of Mitochondrial Connexin 43. [PMID:25552354]	["Pecoraro M", "Sorrentino R", "Francesc	Cardiovascular toxicology	2015	0
Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction [PMID:25676338]	Chen YS, Green CR, Danesh-Meyer HV, Rupe	European journal of pharmaceut	2015	0
Myocardial recovery from ischemia-reperfusion is compromised in the absence of t [PMID:24842912]	["Takawale A", "Fan D", "Basu R", "Shen	Circulation. Heart failure	2014	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning CX43 in their description or question text

No additional research found